

From: [First Name] [Last Name] <email address>
To: [First Name] [Last Name] <email address>
Subject Line: Change Her Expectations for a Better Recovery
Preheader: EXPAREL in a TAP block as part of a multimodal pain management protocol improves women's recovery from surgery

Having trouble viewing this email? [View in your browser.](#)

EXPAREL[®]
(bupivacaine liposome injectable suspension)

MAKE BETTER POSSIBLE




Give women a head start on postsurgical recovery goals with EXPAREL

Dear [First Name][Last Name]

Women want to heal quickly after surgery without complications or pain so that they can get back to their lives. In a recent survey, 96% of US women aged 30 to 50 years said they were motivated to get back to their daily routine following surgery.*

EXPAREL helps lower the barriers to recovery after C-section and hysterectomy in TAP blocks as part of a multimodal protocol^{2,3}



46% LOWER PAIN SCORES^{2†}

From 0 to 3 days:
132.8 vs 246.3;
P<0.001



52% LESS OPIOID USE^{3‡}

From 0 to 3 days:
24.9 vs 51.7 (MED),
mg; P=0.002



39% FASTER TIME TO AMBULATION²

18.7 vs 30.7 hours;
P<0.001



1-DAY SHORTER LOS²

2.9 vs 3.9 days;
P<0.001

[SEE MORE DATA](#)

Speak with an EXPAREL representative

[CONNECT WITH US](#)

LOS=length of stay; MED=morphine equivalent dose; TAP=transversus abdominis plane.

*A 2020 survey of patients who underwent obstetrics/gynecologic surgery.¹

[†]The numeric rating scale used ranged from 0 (no pain) to 10 (worst pain).²

[‡]The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Results from a retrospective chart review in patients who underwent C-section (N=201) with an EXPAREL TAP block (n=101) compared with those who did not receive an EXPAREL TAP block (n=100).²

Results from a randomized control trial in patients undergoing a robotic hysterectomy (N=60) who received an EXPAREL TAP block (n=30) compared with patients who received a bupivacaine HCl TAP block (n=30).³

References: **1.** Pacira BioSciences, Inc. *On the Rebound: What to Expect After Surgery*. May 2020. [Analysis in the report was based on research conducted by Wakefield Research.]; **2.** Baker B, Villadiego LG, Lake YN, et al. Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review. *J Pain Res*. 2018;11:3109-3116; **3.** Hutchins J, Delaney D, Vogel RI, et al. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: a prospective randomized controlled study. *Gynecol Oncol*. 2015;138(3):609-613.

Please see full Prescribing Information [here](#) and Important Safety Information below.

INDICATION

EXPAREL is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

IMPORTANT SAFETY INFORMATION

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is available at [EXPAREL.com](#).

If you wish to unsubscribe from receiving emails such as this, [click here](#).



From: [First Name] [Last Name] <email address>
To: [First Name] [Last Name] <email address>
Subject Line: Change Her Expectations for a Better Recovery
Preheader: EXPAREL in a TAP block as part of a multimodal pain management protocol improves women's recovery from surgery

Having trouble viewing this email? [View in your browser.](#)

EXPAREL[®]
(bupivacaine liposome injectable suspension)

MAKE BETTER POSSIBLE

GET UP
AND
GO

Give women a head start on postsurgical recovery goals with EXPAREL

Dear [First Name] [Last Name]

Women want to heal quickly after surgery without complications or pain so that they can get back to their lives. In a recent survey, 96% of US women aged 30 to 50 years said they were motivated to get back to their daily routine following surgery.^{1*}

EXPAREL helps lower the barriers to recovery after C-section and hysterectomy in TAP blocks as part of a multimodal protocol^{2,3}

46% LOWER PAIN SCORES^{2†}

From 0 to 3 days:
132.8 vs 246.3;
P<0.001

52% LESS OPIOID USE^{3‡}

From 0 to 3 days:
24.9 vs 51.7 (MED),
mg; P=0.002



39% FASTER TIME TO AMBULATION²

18.7 vs 30.7 hours;
P<0.001



1-DAY SHORTER LOS²

2.9 vs 3.9 days;
P<0.001

[SEE MORE DATA](#)

Speak with an EXPAREL representative

[CONNECT WITH US](#)

LOS=length of stay; MED=morphine equivalent dose; TAP=transversus abdominis plane.

*A 2020 survey of patients who underwent obstetrics/gynecologic surgery.¹

†The numeric rating scale used ranged from 0 (no pain) to 10 (worst pain).²

‡The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Results from a retrospective chart review in patients who underwent C-section (N=201) with an EXPAREL TAP block (n=101) compared with those who did not receive an EXPAREL TAP block (n=100).²

Results from a randomized control trial in patients undergoing a robotic hysterectomy (N=60) who received an EXPAREL TAP block (n=30) compared with patients who received a bupivacaine HCl TAP block (n=30).³

References: **1.** Pacira BioSciences, Inc. *On the Rebound: What to Expect After Surgery*. May 2020. [Analysis in the report was based on research conducted by Wakefield Research.]; **2.** Baker B, Villadiego LG, Lake YN, et al. Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review. *J Pain Res*. 2018;11:3109-3116; **3.** Hutchins J, Delaney D, Vogel RI, et al. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: a prospective randomized controlled study. *Gynecol Oncol*. 2015;138(3):609-613.

Please see full Prescribing Information [here](#) and Important Safety Information below.

INDICATION

EXPAREL is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

IMPORTANT SAFETY INFORMATION

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is available at [EXPAREL.com](#).

If you wish to unsubscribe from receiving emails such as this, [click here](#).

PACIRA
BIOSCIENCES, INC.

©2023 Pacira Pharmaceuticals, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc.
5 Sylvan Way, Parsippany, NJ 07054
All rights reserved. PP-EX-US-8511 05/23